Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive publishing date : 2022 - 06 - 10 save search
GSK’s RSV vaccine candidate for older adults, containing Agenus’ QS-21 STIMULON™ as part of GSK’s AS01 adjuvant, reports positive pivotal data supporting initiation of global regulatory submissions
Published: 2022-06-10 (Crawled : 13:00) - biospace.com/
AGEN A | $7.21 24.96% 1.1M
|
Health Technology
|
| O: -6.51%
H: 0.0%
C: 0.0%
qs-21 vaccine positive order
Cogent Biosciences Announces Positive Initial Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
Published: 2022-06-10 (Crawled : 12:20) - biospace.com/
COGT | $7.205 1.19% 480K
|
Health Technology
|
| O: 40.81%
H: 0.0%
C: 0.0%
ongoing trial positive phase 2
Amarin Receives Positive Recommendation from United Kingdom’s (UK) National Institute for Health and Care Excellence (NICE) for Reimbursement of VAZKEPA® (icosapent ethyl)
Published: 2022-06-10 (Crawled : 12:00) - biospace.com/
AMRN | News | $0.8888 2.67% 560K
|
Health Technology
|
| O: -2.17%
H: 0.0%
C: 0.0%
vazkepa care health positive
Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in MELAS Patients at UMDF Mitochondrial Medicine 2022 Symposium
Published: 2022-06-10 (Crawled : 11:00) - ir.cyclerion.com
CYCN | $3.05 110
|
Health Technology
|
| O: -20.73%
H: 0.0%
C: 0.0%
cy6463 topline symposium therapeutics positive
Caribou Biosciences Reports Positive Additional Data from CB-010 Allogeneic CAR-T Cell Therapy Phase 1 ANTLER Trial at the European Hematology Association (EHA) 2022 Hybrid Congress
Published: 2022-06-10 (Crawled : 08:00) - globenewswire.com
CRBU | $4.075 2.13% 540K
|
Health Technology
|
| O: -22.27%
H: 0.0%
C: 0.0%
cb-010 car-t trial positive therapy phase 1
GBT Presents Positive New Real-World Evidence Data at EHA2022 Congress Further Supporting Clinical Use of Oxbryta® (voxelotor) in Sickle Cell Disease
Published: 2022-06-10 (Crawled : 08:00) - globenewswire.com
GBT | $68.49 0.02% -0.02%
|
Health Technology
|
| O: -6.01%
H: 0.0%
C: 0.0%
eha2022 oxbryta disease positive
Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at EHA 2022
Published: 2022-06-10 (Crawled : 08:00) - globenewswire.com
IMGO | $36.01 0.03% 0.0% 0
|
Health Technology
|
| O: -7.77%
H: 0.0%
C: 0.0%
ongoing positive phase 2
Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at EHA 2022
Published: 2022-06-10 (Crawled : 08:00) - globenewswire.com
IMGO | $36.01 0.03% 0.0% 0
|
Health Technology
|
| O: -7.77%
H: 0.0%
C: 0.0%
ongoing positive phase 2
Genentech Announces Positive Data from Broad Blood Cancer Portfolio at European Hematology Association Annual Meeting
Published: 2022-06-10 (Crawled : 08:00) - biospace.com/
FNCTF | News | $11.16 130
|
Communications
| Email alert
Add to watchlist
blood positive cancer
Gainers vs Losers
| 87% | 13% |
Top 10 Gainers
MTTR | News M | $4.64 166.67% 18M
|
AGBA | $2.74 119.2% 52M
|
Finance
CZOO | $9.07 81.76% 22M
|
EDBL | News | $6.56 74.47% 1.8M
|
OPRT | News | $3.37 49.78% 8.9M
|
Finance
MTC | $2.14 37.18% 4.9M
|
Technology Services
VNRX | $0.7945 32.42% 3.1M
|
Health Technology
MLEC | $1.79 27.86% 2.6M
|
n/a
BTCM | $3.45 27.78% 640K
|
Arts, Entertainment, and Recrea...
PALI | $6.29 27.59% 22M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.